With significant upside potential, Spyre Therapeutics Inc. (NASDAQ:SYRE) secures a spot on our list of the 10 Best Debt Free Small Cap Stocks to Buy Now. Spyre Therapeutics Inc. (SYRE) Enrolls First Patient in Its Patient 2 SKYWAY Trial Copyright: alphaspirit / 123RF Stock Photo On September 15, 2025, Spyre Therapeutics Inc. (NASDAQ:SYRE) announced the enrollment of the first patient in its Phase 2 SKYWAY trial targeting multiple autoimmune diseases. This randomized study will assess the company’s lead ...